US FDA Fulfills Annual Antibiotic Guidance Goal With Three Women’s Health Guidances
Final guidance documents for bacterial vaginosis, vulvovaginal candidiasis, and uncomplicated urinary tract infections contain few changes from draft.
You may also be interested in...
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Around the world, government agencies, academic and other researchers and the biopharmaceutical industry have rushed to see what drugs could help treat COVID-19 and the symptoms it causes, and accelerate a vaccine that could help limit the spread of the pandemic. This chart will be updated daily as additional research gets underway.